Results 181 to 190 of about 31,202,450 (314)

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

A Modification for Routine Laboratory Use of Stefanini's Method of Estimating Factor V Activity in Human Oxalated Plasma

Journal of Clinical Pathology, 1953
P. Wolf
semanticscholar   +1 more source

Orbital invasion by an antrochoanal polyp in a factor V-deficient patient: A case report of diagnostic and surgical challenges. [PDF]

Int J Surg Case Rep
Alkheder A, Azar A, Al-Ghabra Y, Almooh K, Alaitouni A, Mustafa A.   +5 more
europepmc   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Investigation of Prothrombin G20210A and <i>Factor V Leiden</i> G1691A Variants in Patients with Acute Coronary Syndrome Presenting to the Emergency Department with Chest Pain. [PDF]

Genes (Basel)
Yukcu F, Kaya M, Can F, Yildirim H.
europepmc   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Successful management of bleeding in a patient with factor V inhibitor by platelet transfusions.

Blood, 1980
J. Chediak, J. Ashenhurst, I. Garlick, R. Desser   +3 more
semanticscholar   +1 more source

Persistent Anticoagulation and Severe Upper Gastrointestinal Bleeding in a Patient With Factor V Leiden: A Case of the Warfarin Reservoir Phenomenon. [PDF]

Cureus
Kammawal Y.
europepmc   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V.

Blood, 1984
C. Fulcher, J. E. Gardiner, J. Griffin, T. Zimmerman   +3 more
semanticscholar   +1 more source